设为首页 中国市场调查彩票平台app下载网 关于彩票平台app下载网 购买流程
彩票平台app下载网
首页 > 英文报告> Xeloda (Breast cancer) Analysis and Forecasts to 2020

Xeloda (Breast cancer) Analysis and Forecasts to 2020

【报告名称:】

Xeloda (Breast cancer) Analysis and Forecasts to 2020

【关 键 词:】

Xeloda (Breast cancer) Analysis and Forecasts

【报告格式:】PDF或WORD格式
【释放日期:】2012年5月
【交付方式:】特快专递或Email电子版
【英文版价格:】英文价格:$2000
分享到:
报告描述
    This report is for multi-user reports, if you have more demand, we will revise the report of the framework, and make a reasonable offer.

报告目录


Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Introduction 5
2.1 Breast Cancer Market 5
2.2 Epidemiology 5
2.3 Report Guidance 7
3 Breast Cancer: Market Characterization 8
3.1 Breast Cancer Market 8
3.2 Breast Cancer Market Forecasts and CAGR 8
3.3 Drivers of Breast Cancer Market 8
3.3.1 High Prevalence 9
3.3.2 Breast Cancer: Most Frequent Cancer in Women 9
3.3.3 Increasing Breast Cancer Incidence Rate 9
3.3.4 Decreasing Breast Cancer Mortality Rate 11
3.3.5 High Survival Rates of Breast Cancer 13
4 Staging of Breast Cancer: Introduction 15
4.1 Distribution of Patients by Stages 15
4.1.1 Stages 15
5 Predictive Biomarker in the Treatment of Breast Cancer 18
6 Treatment Options of Breast Cancer 20
6.1 Stage 0 Breast Cancer: Treatment Options 20
6.2 Early Stage Breast Cancer (Excluding Stage 0) 21
6.3 Metastatic Breast Cancer (MBC) 23
6.3.1 Endocrine Treatment: Adjuvant, First Line and Second Line 23
6.3.2 Cytotoxic Chemotherapy 25
6.3.3 Management of Patients with HER-2 Positive Patients 27
7 Xeloda 29
7.1 Introduction 29
7.2 Mechanism of Action 29
7.3 Clinical Studies 29
7.3.1 Breast Cancer Combination Therapy 29
7.3.2 Breast Cancer Monotherapy 30
7.4 Approval History of Xeloda 30
7.5 Factors Affecting Sales 31
7.5.1 Patent Expiry of Competing Drug 31
7.5.2 Absence of Gemzar, Tykerb and Omnitarg in the Third and Fourth Line of Treatment 31
7.5.3 Approval of Xeloda as an Adjuvant Therapy in Early Breast Cancer 31
7.6 Drug Risk Benefit Score 31
7.6.1 Efficacy 32
7.6.2 Safety 32
7.6.3 Compliance 32
7.6.4 Dosing Convenience 32
7.7 Intensity of Competition 32
7.8 Sales Forecast 33
7.8.1 Target Patient Pool of Xeloda 33
7.8.2 Dosing 34
7.8.3 Market Penetration 34
7.8.4 Annual Cost of Therapy 35
7.8.5 Sales Projection of Xeloda 35
8 Appendix 41
8.1 Market Definitions 41
8.2 Abbreviations 41
8.3 Research Methodology 41
8.3.1 Coverage 41
8.3.2 Secondary Research 42
8.3.3 Forecasting 42
8.3.4 Number of Patients Approved to take the Drug 42
8.3.5 Net Penetration of Drug 43
8.3.6 Net Annual Dosing 44
8.3.7 Annual Cost of Therapy 44
8.3.8 Primary Research 44
8.3.9 Expert Panels 44
8.4 Contact Us 45
8.5 Disclaimer 45
8.6 Sources 45
1.1 List of Tables
Table 1: Breast Cancer, Incidences and Mortality, By Country, 2008-2030 5
Table 2: Breast Cancer, Global, Market Size Forecasts ($bn), 2010–2020 8
Table 3: Five-Year Relative Survival Rates, By Stages 14
Table 4: Efficacy of Xeloda and docetaxel Combination vs. docetaxel Monotherapy 30
Table 5: Response Rates in Breast Cancer Monotherapy with Xeloda 30
Table 6: Approval History of Xeloda 30
Table 7: Drug Risk Benefit Score of Xeloda as a Combination Therapy 31
Table 8: Drug Risk Benefit Score of Xeloda as Monotherapy 32
Table 9: Annual Cost of Therapy of Xeloda 35
Table 10: Xeloda, Breast Cancer, Global, Sales Estimates ($m), 2002–2009 36
Table 11: Xeloda, Breast Cancer, Global, Sales Forecasts ($m), 2010–2020 36
Table 12: Xeloda, Breast Cancer, the US, Sales Estimates ($m), 2002–2009 37
Table 13: Xeloda, Breast Cancer, the US, Sales Forecasts ($m), 2010–2020 37
Table 14: Xeloda, Breast Cancer, EU, Sales Estimates ($m), 2002–2009 38
Table 15: Xeloda, Breast Cancer, EU, Sales Forecasts ($m), 2010–2020 38
Table 16: Xeloda, Breast Cancer, Japan, Sales Estimates ($m), 2003–2009 39
Table 17: Xeloda, Breast Cancer, Japan, Sales Forecasts ($m),2010–2020 39
1.2 List of Figures
Figure 1: Distribution by Incidence and Mortality, Most Commonly Diagnosed Cancers, Worldwide, 2010 6
Figure 2: Breast Cancer, Global, Market Size Forecasts ($bn), 2010–2020 8
Figure 3: Top 10 Most Frequent Cancers on Incidence-Mortality Matrix, Worldwide, 2010 9
Figure 4: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 10
Figure 5: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 10
Figure 6: Breast Cancer, Incidence, Worldwide, 2008-2030 11
Figure 7: All Cancers, Incidence, Worldwide, 2008-2030 11
Figure 8: Mortality per 100,000, Breast Cancer, Selected Countries, 1975-2005 12
Figure 9: Mortality per 100,000, Breast Cancer, Selected Countries, 1975-2005 12
Figure 10: Breast Cancer, Mortality, Worldwide, 2008-2030 13
Figure 11: All Cancers, Mortality, Worldwide, 2008-2030 13
Figure 12: Broad Classification of Breast Cancer, By Type 15
Figure 13: Classification of Non-Invasive Breast Cancer, By CIS 15
Figure 14: Classification of Invasive Breast Cancer, By Stages 16
Figure 15: Classification of Invasive Breast Cancer, By Treatment 16
Figure 16: Classification of Metastatic or Advanced Breast Cancer 16
Figure 17: Classification of Early Stage Breast Cancer (Excluding Stage 0) 17
Figure 18: Classification of Locally Advanced Breast Cancer 17
Figure 19: Metastatic Breast Cancer Classification 17
Figure 20: Current Molecular Biomarkers used in the Clinical Management of Breast Cancer 18
Figure 21: Breast Cancer Intrinsic Sub Types used for Deciding Treatment Options for MBC 19
Figure 22: Breast Cancer Types in Decreasing Order of their Aggressiveness 19
Figure 23: Treatment Options, DCIS Breast Cancer 20
Figure 24: Treatment Options, LCIS Breast Cancer 21
Figure 25: Treatment Options, Stages I, II and IIIA 21
Figure 26: Treatment Options, Stages I, II and IIIA (HR Positive and Premenopausal Breast Cancer) 22
Figure 27: Treatment Options, Stages I, II and IIIA (HR Negative, Pre and Postmenopausal Breast Cancer) 22
Figure 28: Treatment Options, Stages I, II and IIIA (HR Positive Postmenopausal Breast Cancer) 23
Figure 29: Adjuvant Therapy for HR Positive, HER2 Negative Metastatic Breast Cancer 24
Figure 30: Hormonal Therapy in Adjuvant Setting in HR Positive, HER2 Negative MBC 24
Figure 31: Adjuvant and First Line Therapy for HR Negative, HER2 Negative Metastatic Breast Cancer 26
Figure 32: Treatment Options, HR Negative and HER2 Positive Metastatic Breast Cancer 27
Figure 33: Drug Model Diagram of Xeloda in the US and EU 33
Figure 34: Drug Model Diagram of Xeloda in Japan 34
Figure 35: Xeloda, Breast Cancer, Global, Sales Estimates ($m), 2002–2020 36
Figure 36: Xeloda, Breast Cancer, the US, Sales Estimates ($m), 2002–2020 37
Figure 37: Xeloda, Breast Cancer, EU, Sales Estimates ($m), 2002–2020 38
Figure 38: Xeloda, Breast Cancer, Japan, Sales Estimates ($m), 2003-2020 39
Figure 39: Xeloda, Breast Cancer, Global, Sales Distribution by Country ($m), 2012 40
Figure 40: Drug Model Diagram 43
Figure 41: Patients Approved to take the Drug 44

NO:12-12

彩票平台app下载网电话订购

电 话: 56287808
传 真:010-87661981
E_mail:cnscdc@hjsdicr.com

彩票平台app下载网在线订购

MSN:
scdcbg@hotmail.com
lixin8866@hotmail.com
市场调查网QQ

订购流程

为什么选择我们


相关链接